Cargando…

Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice

BACKGROUND: Renal tubulointerstitial fibrosis is a common feature of the final stage of nearly all cause types of chronic kidney disease. Although classic peroxisome proliferator-activated receptor γ (PPARγ) agonists have a protective effect on diabetic nephropathy, much less is known about their di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bae, Kwi-Hyun, Seo, Jung Beom, Jung, Yun-A, Seo, Hye-Young, Kang, Sun Hee, Jeon, Hui-Jeon, Lee, Jae Man, Lee, Sungwoo, Kim, Jung-Guk, Lee, In-Kyu, Jung, Gwon-Soo, Park, Keun-Gyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368110/ https://www.ncbi.nlm.nih.gov/pubmed/28256116 http://dx.doi.org/10.3803/EnM.2017.32.1.115

Ejemplares similares

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Kim, Mi-Jin, et al.
Publicado: (2020)

Association between household size, residential area, and osteoporosis: analysis of 2008 to 2011 Korea National Health and Nutrition Examination Survey
por: Kim, Sung-Woo, et al.
Publicado: (2016)

Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018)

Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome
por: Bae, Kwi-Hyun, et al.
Publicado: (2018)

Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome
por: Seo, Jung Beom, et al.
Publicado: (2019)

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects
por: Kim, Yu Kyong, et al.
Publicado: (2021)

Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
por: Kim, Kyoung Min, et al.
Publicado: (2017)

Identification of Selective ERRγ Inverse Agonists
por: Kim, Jina, et al.
Publicado: (2016)

Transcriptional Regulation of Fibroblast Growth Factor 21 Expression
por: Bae, Kwi-Hyun, et al.
Publicado: (2014)

Mesenchymal stem cell-derived microparticles ameliorate peritubular capillary rarefaction via inhibition of endothelial-mesenchymal transition and decrease tubulointerstitial fibrosis in unilateral ureteral obstruction
por: Choi, Hoon Young, et al.
Publicado: (2015)

Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs
por: Lee, Min A, et al.
Publicado: (2017)

Cilostazol inhibits insulin-stimulated expression of sterol regulatory binding protein-1c via inhibition of LXR and Sp1
por: Jung, Yun-A, et al.
Publicado: (2014)

Clusterin/Apolipoprotein J Attenuates Angiotensin II-Induced Renal Fibrosis
por: Jung, Gwon-Soo, et al.
Publicado: (2014)

Clinical Characteristics for 348 Patients with Adrenal Incidentaloma
por: Kim, Jongho, et al.
Publicado: (2013)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

γ-Selective C(sp(3))–H amination via controlled migratory hydroamination
por: Lee, Changseok, et al.
Publicado: (2021)

Changes in the Bone Mineral Density of Femur Neck and Total Hip Over a 52-Week Treatment with Lobeglitazone
por: Lee, Da Young, et al.
Publicado: (2017)

Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
por: Seo, Hye-Young, et al.
Publicado: (2023)

Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice
por: Choi, Bong-Hoi, et al.
Publicado: (2018)

MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism
por: Kim, Seok-Ho, et al.
Publicado: (2019)

Ablation of Gadd45β ameliorates the inflammation and renal fibrosis caused by unilateral ureteral obstruction
por: Moon, Sung‐Je, et al.
Publicado: (2020)

Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway
por: Jin, Jun-Qing, et al.
Publicado: (2021)

Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
por: Seo, Da Hea, et al.
Publicado: (2022)

Low-Normal Free Thyroxine Levels in Euthyroid Male Are Associated with Prediabetes
por: Kim, Sung Woo, et al.
Publicado: (2019)

Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Restores Alveolar and Pulmonary Vascular Development in a Rat Model of Bronchopulmonary Dysplasia
por: Lee, Hyun Ju, et al.
Publicado: (2014)

Antiallergic Function of KR62980, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in a Mouse Allergic Rhinitis Model
por: Lee, Ji-Eun, et al.
Publicado: (2015)

Anti-Fibrotic Effect of Natural Toxin Bee Venom on Animal Model of Unilateral Ureteral Obstruction
por: An, Hyun Jin, et al.
Publicado: (2015)

FcγRIIb-SHIP2 axis links Aβ to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model
por: Kam, Tae-In, et al.
Publicado: (2016)

Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages
por: Jeong, Dabin, et al.
Publicado: (2021)

The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition
por: Lee, Yu Seol, et al.
Publicado: (2018)

The Protective Effect of Melittin on Renal Fibrosis in an Animal Model of Unilateral Ureteral Obstruction
por: An, Hyun-Jin, et al.
Publicado: (2016)

Melatonin inhibits vascular smooth muscle cell proliferation and apoptosis through upregulation of Sestrin2
por: Lee, Seunghyeong, et al.
Publicado: (2020)

Peroxisome proliferator-activated receptor γ agonist suppresses human telomerase reverse transcriptase expression and aromatase activity in eutopic endometrial stromal cells from endometriosis
por: Chang, Hye Jin, et al.
Publicado: (2013)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
por: Yoo, Joonsang, et al.
Publicado: (2023)

A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
por: Kim, Bo-Yeon, et al.
Publicado: (2022)

Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study
por: Lim, Soo, et al.
Publicado: (2020)

Year-Long Trend in Glycated Hemoglobin Levels in Patients with Type 2 Diabetes during the COVID-19 Pandemic
por: Jin, Jonghwa, et al.
Publicado: (2021)

Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
por: Lee, Yong-ho, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_umpr9rms5ngatjjub4pprc6aq2